Furthermore, a pooled analysis of the two phase III trials among 2025 mild-to-moderate AD patients (considering the distribution of ApoE4 allele) revealed a positive trend in Clinical Dementia Rating Scale Sum of Boxes scores (CDR-SB) and marked differences in ADAS-cog scores in homozygote individuals (who received 150 mg two times a day).
← all excerpts
Anti-Alzheimer's Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential.
1
—
—